Expression Profile of Endoglin in Different Grades of Endometrial Cancer
| Autor: | Konrad Dziobek, Andrzej Plewka, Nikola Zmarzły, Dariusz Dąbruś, Marcin Oplawski, Beniamin Grabarek, Iwona Adwent, Dariusz Boroń |
|---|---|
| Jazyk: | angličtina |
| Rok vydání: | 2018 |
| Předmět: |
Endothelium
medicine.drug_class Angiogenesis Pharmaceutical Science Receptors Cell Surface Monoclonal antibody Mice angiogenesis Endometrial cancer Antigens CD hemic and lymphatic diseases Biomarkers Tumor otorhinolaryngologic diseases medicine Animals Humans molecular marker endoglin Neovascularization Pathologic business.industry Cancer Endoglin medicine.disease Endometrial Neoplasms medicine.anatomical_structure Case-Control Studies Cancer cell immunohistochemistry Cancer research Immunohistochemistry Female Endothelium Vascular Neoplasm Grading business vascular endothelium Signal Transduction Biotechnology |
| Zdroj: | Current Pharmaceutical Biotechnology. 19(12):990-995 |
| ISSN: | 1389-2010 |
| Popis: | Background Endoglin is a marker of active, proliferating endothelial cells of blood vessels. In many cancers, it is present in both peripheral vessels and vessels located inside the tumor. Endoglin is more specific and sensitive compared to other tumor angiogenesis markers. It is suggested that endoglin can be considered a reliable marker of disease outcome. Objective The aim of the study was to assess the expression of endoglin and to determine its potential usefulness as a complementary molecular marker of endometrial cancer. Method The study included 60 women who underwent hysterectomy: 45 with endometrioid endometrial cancer (study group) and 15 without neoplastic changes (control group). The study group was further divided according to the degree of histological differentiation: G1, 17; G2, 15; and G3, 13. The expression of endoglin was determined immunohistochemically with mouse anti-Endoglin monoclonal antibody. The obtained reactions were evaluated using light microscopy. Results Analysis of endoglin expression in endothelium showed that it reached 145% of the control. In G2, we observed that the endoglin level decreased and was similar to the control, while in G3 it increased and was even higher than in G1. In cancer cells, endoglin expression increased with the grade of endometrial cancer. Conclusion Endoglin can be considered a valuable complementary molecular marker, allowing to visualize the advancement of the cancer process, including endometrial cancer. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|